Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Girentuximab

Catalog #:   DHH37201 Specific References (100) DATASHEET
Host species: Chimeric
Isotype: IgG1-kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHH37201

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Chimeric

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

Membrane antigen MN, P54/58N, Carbonic anhydrase 9, Renal cell carcinoma-associated antigen G250, CA-IX, CAIX, pMW1, Carbonic anhydrase IX, RCC-associated antigen G250, Carbonate dehydratase IX, CA9, MN, G250

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q16790

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

WX-G250, cG250, CAS: 916138-87-9

Clone ID

Girentuximab

Data Image
  • SDS-PAGE
    SDS PAGE for Girentuximab
References

Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo, PMID: 30487460

Kidney cancer: Finding a niche for girentuximab in metastatic renal cell carcinoma, PMID: 27349371

Lesion detection by [ 89 Zr]Zr-DFO-girentuximab and [ 18 F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma, PMID: 31172212

Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111 In-girentuximab, PMID: 31768601

Positron Emission Tomography/Computed Tomography with 89 Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion, PMID: 29730017

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial, PMID: 27787547

Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma, PMID: 23453421

Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab, PMID: 33742975

Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC, PMID: 25748241

Preclinical validation of 111 In-girentuximab-F(ab') 2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts, PMID: 28789809

Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab, PMID: 24752673

Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma, PMID: 24396030

CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models, PMID: 31827111

Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer, PMID: 23204838

Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma, PMID: 26706103

Girentuximab bringt keinen klinischen Benefit, PMID: 28854471

Phase I study to assess safety, biodistribution and radiation dosimetry for 89 Zr-girentuximab in patients with renal cell carcinoma, PMID: 33651116

Re: Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders. Indium-111-labeled girentuximab immunospect as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol 2013;63:1101-6, PMID: 23849417

Reply to John Samuel Banerji's letter to the editor re: Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol 2013;63:1101-6, PMID: 23859982

Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study, PMID: 27103404

Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma, PMID: 22980441

Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors, PMID: 26878088

Molecular imaging of urogenital diseases, PMID: 24484747

Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models, PMID: 30550290

Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management, PMID: 32998233

Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors, PMID: 28926956

Diagnostic Challenges of Kidney Cancer: A Systematic Review of the Role of Positron Emission Tomography-Computerized Tomography, PMID: 27140072

PET/CT with (124)I-cG250: great potential and some open questions, PMID: 25055257

Molecular imaging of renal cell carcinoma, PMID: 18992614

Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study, PMID: 29721070

The role of molecular imaging in the characterization of renal masses, PMID: 29319547

Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?, PMID: 24215158

Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts, PMID: 30464696

Noninvasive determination of renal tumor histology utilizing molecular imaging, PMID: 27888980

Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma, PMID: 23638744

Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial, PMID: 23213092

G250: a carbonic anhydrase IX monoclonal antibody, PMID: 15717944

Antibody-based therapeutics to watch in 2011, PMID: 21051951

Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma, PMID: 23759990

Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule, PMID: 25434612

Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy, PMID: 20359812

Perioperative Management of Localized Kidney Cancer: Watching and Waiting, PMID: 27787546

Inhibition of V-ATPase and carbonic anhydrases as interference strategy with tumor acidification processes, PMID: 22360559

Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model, PMID: 25230982

Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma, PMID: 27418270

6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland, PMID: 21441785

CA IX stratification based on cancer treatment: a patent evaluation of US2016/0002350, PMID: 27575256

Management of urological malignancies: Has positron emission tomography/computed tomography made a difference?, PMID: 25624571

Fabrication of mAb G250-SPIO molecular magnetic resonance imaging nanoprobe for the specific detection of renal cell carcinoma in vitro, PMID: 24999987

PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors, PMID: 20554724

Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery., PMID:40408016

STARLITE 1: Phase 1b/2 Study of Combined 177Lu-Girentuximab plus Cabozantinib and Nivolumab in Treatment-naïve Patients with Advanced Clear-cell Renal Cell Carcinoma., PMID:40288950

Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care., PMID:40227816

Re: Brian Shuch, Allan J. Pantuck, Jean-Christophe Bernhard, et al. [89Zr]Zr-girentuximab for PET-CT Imaging of Clear-cell Renal Cell Carcinoma: A Prospective, Open-label, Multicentre, Phase 3 Trial. Lancet Oncol 2024;25:1277-87., PMID:40204601

Antibody-drug conjugates and radioconjugates targeting carbonic anhydrase IX and XII in hypoxic tumors: Bench to clinical applications., PMID:40154235

Initial clinical experience with Zr-Girentuximab PET-CT for the evaluation of renal masses in patients with solitary kidneys., PMID:39947297

DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma., PMID:39884775

Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?, PMID:39814588

Molecular imaging targeting carbonic anhydrase 9 in clear-cell renal cell carcinoma: more than meets the eye., PMID:39756448

Preclinical evaluation and automated synthesis of [89Zr]ZrDFOSquaramide-girentuximab for diagnostic imaging of carbonic anhydrase IX positive tumours., PMID:39589414

[89Zr]Zr-girentuximab PET-CT imaging to diagnose, characterize, and differentiate clear-cell renal cell carcinoma., PMID:39520979

Re: [89Zr]Zr-Girentuximab for PET-CT Imaging of Clear-cell Renal Cell Carcinoma: A Prospective, Open-label, Multicentre, Phase 3 Trial., PMID:39443275

Imaging in Renal Cell Carcinoma Detection., PMID:39335784

[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial., PMID:39270701

Molecular imaging for non-invasive risk stratification of renal masses., PMID:39054210

Imaging modalities for characterising T1 renal tumours: A systematic review and meta-analysis of diagnostic accuracy., PMID:39022655

Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma., PMID:38948062

Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP)., PMID:38864246

Efficacy Assessment of Post-nephrectomy Adjuvant Therapies in Patients with Renal Cell Carcinoma., PMID:38494564

Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX., PMID:38425522

Insights into Renal Cell Carcinoma with Novel Imaging Approaches., PMID:37302934

Molecular Imaging Diagnosis of Renal Cancer Using 99mTc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques., PMID:36832081

[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma., PMID:36394882

89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma., PMID:35428649

Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review., PMID:35216855

Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models., PMID:34485720

Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab., PMID:33742975

Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma., PMID:33651116

Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management., PMID:32998233

CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models., PMID:31827111

Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab., PMID:31768601

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma., PMID:31172212

Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models., PMID:30550290

Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo., PMID:30487460

Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts., PMID:30464696

Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion., PMID:29730017

Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study., PMID:29721070

The role of molecular imaging in the characterization of renal masses., PMID:29319547

Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors., PMID:28926956

[Not Available]., PMID:28854471

Preclinical validation of 111In-girentuximab-F(ab')2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts., PMID:28789809

Noninvasive determination of renal tumor histology utilizing molecular imaging., PMID:27888980

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial., PMID:27787547

Perioperative Management of Localized Kidney Cancer: Watching and Waiting., PMID:27787546

CA IX stratification based on cancer treatment: a patent evaluation of US2016/0002350., PMID:27575256

Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma., PMID:27418270

Kidney cancer: Finding a niche for girentuximab in metastatic renal cell carcinoma., PMID:27349371

Diagnostic Challenges of Kidney Cancer: A Systematic Review of the Role of Positron Emission Tomography-Computerized Tomography., PMID:27140072

Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study., PMID:27103404

Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors., PMID:26878088

Datasheet

Document Download

Research Grade Girentuximab.pdf

 

$ 372
Product specifications
100 μg 372 1 mg 1486

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Girentuximab [DHH37201]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only